iopidine ey.dro.sol 0,5% (w/v)
novartis (hellas) a.e.b.e. 12ο χλμ. Εθν.οδού Νο1,, 144 51 144 51, Μεταμόρφωση Αττικής 2811712 - apraclonidine hydrochloride - ey.dro.sol (ΟΦΘΑΛΜΙΚΕΣ ΣΤΑΓΟΝΕΣ, ΔΙΑΛΥΜΑ) - 0,5% (w/v) - apraclonidine hydrochloride 5,75mg - apraclonidine
catapresan tab 0,150mg/tab
glenwood gesellschaft mit beschrankter haftung pharmazeutische erzeugnisse, germany arabellastraße 17, bavaria 81925 münchen - - clonidine hydrochloride - tab (ΔΙΣΚΙΟ) - 0,150mg/tab - clonidine hydrochloride 0,15mg - clonidine
catapres sol.iv.inf 150mcg/ml
ΙΦΕΤ ΑΕ 18ο χλμ. Λεωφ. Μαραθώνος,, 153 51 153 51, Παλλήνη Αττικής 210.6603400-6603522 - clonidine hydrochloride - sol.iv.inf (ΔΙΑΛΥΜΑ ΓΙΑ ΕΝΔΟΦΛΕΒΙΑ ΕΓΧΥΣΗ) - 150mcg/ml - clonidine hydrochloride - clonidine
catapressan tab 0,150 μg/tab
glenwood gesellschaft mit beschrankter haftung pharmazeutische erzeugnisse, germany arabellastraße 17, bavaria 81925 münchen - - clonidine hydrochloride - tab (ΔΙΣΚΙΟ) - 0,150 Μg/tab - clonidine hydrochloride 0,15mg - clonidine
catapresan tab 0,150mg/tab
glenwood gesellschaft mit beschrankter haftung pharmazeutische erzeugnisse, germany arabellastraße 17, bavaria 81925 münchen - - clonidine hydrochloride - tab (ΔΙΣΚΙΟ) - 0,150mg/tab - clonidine hydrochloride 0,15mg - clonidine
catapres inj.sol 150mcg/ml
glenwood gmbh pharmazeutische erzeugnisse, germany arabellastrasse 17 , bavaria 81925 munich - - clonidine hydrochloride - inj.sol (ΕΝΕΣΙΜΟ ΔΙΑΛΥΜΑ) - 150mcg/ml - clonidine hydrochloride 150mcg - clonidine
sitagliptin / metformin hydrochloride mylan
mylan ireland limited - sitagliptin hydrochloride monohydrate, metformin hydrochloride - Σακχαρώδης διαβήτης τύπου 2 - Φάρμακα που χρησιμοποιούνται στον διαβήτη - for adult patients with type 2 diabetes mellitus:sitagliptin/metformin hydrochloride mylan is indicated as an adjunct to diet and exercise to improve glycaemic control in patients inadequately controlled on their maximal tolerated dose of metformin alone or those already being treated with the combination of sitagliptin and metformin. sitagliptin/metformin hydrochloride mylan is indicated in combination with a sulphonylurea (i. θεραπεία τριπλού συνδυασμού) ως επιπρόσθετο στη δίαιτα και την άσκηση σε ασθενείς που δεν ελέγχονται επαρκώς με μέγιστη ανεκτή για αυτούς δόση μετφορμίνης και σουλφονυλουρίας. sitagliptin/metformin hydrochloride mylan is indicated as triple combination therapy with a peroxisome proliferator-activated receptor gamma (pparg) agonist (i. , a thiazolidinedione) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a pparg agonist. sitagliptin/metformin hydrochloride mylan is also indicated as add-on to insulin (i. , triple combination therapy) as an adjunct to diet and exercise to improve glycaemic control in patients when stable dose of insulin and metformin alone do not provide adequate glycaemic control.
vildagliptin / metformin hydrochloride accord
accord healthcare s.l.u. - metformin hydrochloride, vildagliptin - Σακχαρώδης διαβήτης τύπου 2 - Φάρμακα που χρησιμοποιούνται στον διαβήτη - vildagliptin/metformin hydrochloride accord is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus:- in patients who are inadequately controlled with metformin hydrochloride alone. - in patients who are already being treated with the combination of vildagliptin and metformin hydrochloride, as separate tablets. - in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate glycaemic control (see sections 4. 4, 4. 5 και 5. 1 για διαθέσιμα δεδομένα σχετικά με διαφορετικούς συνδυασμούς).
sitagliptin / metformin hydrochloride sun
sun pharmaceutical industries europe b.v. - sitagliptin fumarate, metformin hydrochloride - Σακχαρώδης διαβήτης τύπου 2 - Φάρμακα που χρησιμοποιούνται στον διαβήτη - for adult patients with type 2 diabetes mellitus:sitagliptin/metformin hydrochloride sun is indicated as an adjunct to diet and exercise to improve glycaemic control in patients inadequately controlled on their maximal tolerated dose of metformin alone or those already being treated with the combination of sitagliptin and metformin. sitagliptin/metformin hydrochloride sun is indicated in combination with a sulphonylurea (i. θεραπεία τριπλού συνδυασμού) ως επιπρόσθετο στη δίαιτα και την άσκηση σε ασθενείς που δεν ελέγχονται επαρκώς με μέγιστη ανεκτή για αυτούς δόση μετφορμίνης και σουλφονυλουρίας. sitagliptin/metformin hydrochloride sun is indicated as triple combination therapy with a peroxisome proliferator-activated receptor gamma (pparγ) agonist (i. , a thiazolidinedione) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a pparγ agonist. sitagliptin/metformin hydrochloride sun is also indicated as add-on to insulin (i. , triple combination therapy) as an adjunct to diet and exercise to improve glycaemic control in patients when stable dose of insulin and metformin alone do not provide adequate glycaemic control.
metformin hydrochloride/rosemont oral.sol 500mg/5ml
rafarm a.e.b.e. ΚΟΡΙΝΘΟΥ 12, 15451 Ν. ΨΥΧΙΚΟ 6776550, 6747086 - metformin hydrochloride - oral.sol (ΠΟΣΙΜΟ ΔΙΑΛΥΜΑ) - 500mg/5ml - metformin hydrochloride 500mg - metformin